Evidence map›Paper›PMID 39734788›Full record

ArticleChina CDC weekly2024

Post-Marketing Surveillance of Adverse Events Following Meningococcal Vaccination - China, 2013-2021.

Yuyang Xu, Keli Li, Yan Li, Yuan Li, Lina Zhang, Chunxiang Fan, Minrui Ren, Zundong Yin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in China CDC weekly, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuyang XuDepartment of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou City, Zhejiang Province, China.
Keli LiNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Yan LiNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Yuan LiNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Lina ZhangNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Chunxiang FanNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Minrui RenNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
Zundong YinNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

What is already known about this topic?: From 2010 to 2012, the incidence of adverse vaccine reactions from meningococcal vaccine (MenV) in China ranged from 8.46 to 56.30 per 100,000 doses. What is added by this report?: From 2013 to 2021, the overall reported rate of adverse events following immunization (AEFI) of five types of market-authorized MenV-containing vaccines in China was 37.87 per 100,000 doses administered, with a reported incidence of adverse vaccine reactions of 37.39 per 100,000 doses. The reported incidence of adverse vaccine reactions was comparable to that from 2010 to 2012 and perceived to be within an acceptable range. Most rare vaccine reactions were allergic rashes, and most of these cases were transient and non-serious. What are the implications for public health practice?: In China, the incidence of AEFI was very low, and serious abnormal reactions were extremely rare. We should continue to carry out technical training for vaccinators and on-site treatment capabilities to improve emergency treatment for anaphylactic shock and other serious events and ensure the continued safety of vaccination.

Indexed as

adverse eventsmeningococcalPost-marketing surveillancevaccinations

Identifiers

PMID39734788
PMCPMC11673179

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.